These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 27868278)

  • 1. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.
    Sagwa EL; Souverein PC; Ribeiro I; Leufkens HG; Mantel-Teeuwisse AK
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):1-8. PubMed ID: 27868278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-related nephrotoxic and ototoxic reactions : a link through a predictive mechanistic commonality.
    Verdel BM; van Puijenbroek EP; Souverein PC; Leufkens HG; Egberts AC
    Drug Saf; 2008; 31(10):877-84. PubMed ID: 18759511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
    Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
    Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.
    Arnold A; Cooke GS; Kon OM; Dedicoat M; Lipman M; Loyse A; Chis Ster I; Harrison TS
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
    Shibeshi W; Sheth AN; Admasu A; Berha AB; Negash Z; Yimer G
    BMC Pharmacol Toxicol; 2019 May; 20(1):31. PubMed ID: 31122273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and tolerability of the second-line injectable antituberculosis drugs in children.
    Garcia-Prats AJ; Schaaf HS; Hesseling AC
    Expert Opin Drug Saf; 2016 Nov; 15(11):1491-1500. PubMed ID: 27548570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
    Wrohan I; Redwood L; Ho J; Velen K; Fox GJ
    Int J Tuberc Lung Dis; 2021 Jan; 25(1):23-30. PubMed ID: 33384041
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
    Sogebi OA; Adefuye BO; Adebola SO; Oladeji SM; Adedeji TO
    Auris Nasus Larynx; 2017 Aug; 44(4):404-410. PubMed ID: 27832910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
    Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
    Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy.
    Perumal R; Abdelghani N; Naidu N; Yende-Zuma N; Dawood H; Naidoo K; Singh N; Padayatchi N
    J Acquir Immune Defic Syndr; 2018 Aug; 78(5):536-542. PubMed ID: 29683992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of audiometric monitoring in patients with multidrug-resistant tuberculosis.
    Vasconcelos KA; Frota SMMC; Ruffino-Netto A; Kritski AL
    Rev Soc Bras Med Trop; 2017; 50(5):646-651. PubMed ID: 29160511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database.
    Pugi A; Bonaiuti R; Maggini V; Moschini M; Tuccori M; Leone R; Rossi M; Motola D; Piccinni C; Ferrazin F; Sottosanti L; Mugelli A; Vannacci A; Lapi F
    Am J Health Syst Pharm; 2013 Jun; 70(12):1039-46. PubMed ID: 23719881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
    Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
    Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Have we missed reporting adverse drug reactions under Revised National TB Control Programme?' - A mixed method study in Bengaluru, India.
    Krishnappa L; Gadicherla S; Chidambaram P; Anuradha HV; Somanna SN; Naik PR; Das A; Narasimhaiah S; Nagaraja SB
    Indian J Tuberc; 2020 Jan; 67(1):20-28. PubMed ID: 32192612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016.
    Cegielski JP; Chan PC; Lan Z; Udwadia ZF; Viiklepp P; Yim JJ; Menzies D
    Clin Infect Dis; 2021 Dec; 73(11):e3929-e3936. PubMed ID: 33124668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.
    Sturdy A; Goodman A; José RJ; Loyse A; O'Donoghue M; Kon OM; Dedicoat MJ; Harrison TS; John L; Lipman M; Cooke GS
    J Antimicrob Chemother; 2011 Aug; 66(8):1815-20. PubMed ID: 21642291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase.
    Motola D; Donati M; Biagi C; Calamelli E; Cipriani F; Melis M; Monaco L; Vaccheri A; Ricci G
    Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1164-1171. PubMed ID: 28653802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
    Masuka JT; Khoza S
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands.
    Scholl JH; van Puijenbroek EP
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1361-1367. PubMed ID: 27686554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.